Stockscreener 앱 받기
4.68
1.19%
0.09
전일 마감가:
$4.59
열려 있는:
$4.56
하루 거래량:
1.08M
Relative Volume:
0.88
시가총액:
$251.66M
수익:
$217.25M
순이익/손실:
$-50.92M
주가수익비율:
-4.68
EPS:
-1
순현금흐름:
$-100.85M
1주 성능:
-29.42%
1개월 성능:
-45.36%
6개월 성능:
-69.04%
1년 성능:
-77.68%
1일 변동 폭
$4.53
$4.81
1주일 범위
$4.32
$5.35
52주 변동 폭
$4.32
$25.42
Prothena Corporation Plc Stock (PRTA) Company Profile
명칭
Prothena Corporation Plc
전화
011-353-1-236-2500
주소
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
PRTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
4.675 | 246.53M | 217.25M | -50.92M | -100.85M | -1.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.47 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.80 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.37 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.92 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
495.15 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-05-27 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-05-27 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-27 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-01-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-04-24 | 개시 | SVB Securities | Outperform |
| 2023-01-27 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-11-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-06-18 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-08 | 재확인 | Oppenheimer | Outperform |
| 2021-05-26 | 개시 | Citigroup | Buy |
| 2021-02-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-02-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-02 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-12-07 | 개시 | H.C. Wainwright | Buy |
| 2020-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-11-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-05-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-04-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-04-05 | 재확인 | Barclays | Overweight |
| 2017-11-20 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2017-09-29 | 재확인 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Jefferies | Buy |
| 2017-04-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-04-12 | 개시 | Piper Jaffray | Overweight |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-12-21 | 개시 | SunTrust | Buy |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-08-04 | 재확인 | Barclays | Overweight |
| 2016-05-13 | 개시 | Barclays | Overweight |
| 2016-02-19 | 재확인 | Wedbush | Outperform |
| 2016-01-21 | 개시 | Credit Suisse | Outperform |
모두보기
Prothena Corporation Plc 주식(PRTA)의 최신 뉴스
ProShare Advisors LLC Buys 3,312 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
Piper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial Discontinuation - MSN
Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure - MSN
Prothena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Chardan Capital Decreases Earnings Estimates for Prothena - Defense World
Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails - MSN
H.C. Wainwright Maintains Buy Rating on Prothena Corporation (NASDAQ:PRTA), Cuts PT - Insider Monkey
FY2027 EPS Estimates for Prothena Decreased by HC Wainwright - Defense World
Prothena (NASDAQ:PRTA) Given “Underperform” Rating at Bank of America - Defense World
Bank of America Reiterates “Underperform” Rating for Prothena (NASDAQ:PRTA) - Defense World
Prothena (NASDAQ:PRTA) Receives “Underperform” Rating from Bank of America - Defense World
The Prothena Corporation plc (NASDAQ:PRTA) Analysts Have Been Trimming Their Sales Forecasts - simplywall.st
BofA cuts Prothena stock rating, slashes target to $4 By Investing.com - Investing.com Nigeria
Prothena Corp (PRTA) Sees Downgrade and Price Target Cut by B of A Securities | PRTA Stock News - GuruFocus
Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform - Insider Monkey
BofA Securities Downgrades Prothena to Underperform From Neutral, $4 Price Target - marketscreener.com
Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | P - GuruFocus
Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | PRTA Stock News - GuruFocus
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down - MSN
Prothena (PRTA) Downgraded by BofA Analyst with Lower Price Targ - GuruFocus
Prothena (NASDAQ:PRTA) Price Target Lowered to $81.00 at Piper Sandler - Defense World
Prothena (NASDAQ:PRTA) Price Target Cut to $29.00 by Analysts at JMP Securities - Defense World
Prothena (NASDAQ:PRTA) Lowered to Hold Rating by Jefferies Financial Group - Defense World
Prothena (NASDAQ:PRTA) Given New $14.00 Price Target at HC Wainwright - Defense World
Prothena (NASDAQ:PRTA) Given New $18.00 Price Target at Chardan Capital - Defense World
Traders Purchase High Volume of Put Options on Prothena (NASDAQ:PRTA) - Defense World
Prothena (PRTA) Shares Plunge After Key Trial Setback - GuruFocus
Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place (PRTA) - Seeking Alpha
Peninsula biotech Prothena falters — again — and layoffs are on the waySan Francisco Business Times - The Business Journals
Prothena Shares Fall, Stock Downgraded by Multiple Research Firms After Birtamimab Development Discontinued - marketscreener.com
Prothena Corp (PRTA) Downgraded by Oppenheimer | PRTA Stock News - GuruFocus
Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results - Insider Monkey
Prothena stock hits 52-week low amid downgrades (PRTA:NASDAQ) - Seeking Alpha
Prothena Corp (PRTA) Sees Target Price Reduction by Piper Sandle - GuruFocus
Piper Sandler cuts Prothena stock target to $81 from $110 By Investing.com - Investing.com UK
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Cantor Fitzgerald cuts Prothena stock rating to Neutral By Investing.com - Investing.com UK
Prothena Corp (PRTA) Target Price Slashed by JMP Securities | PRTA Stock News - GuruFocus
Prothena (PRTA) Downgraded Following Unsuccessful Phase 3 Trial - GuruFocus
Expert Outlook: Prothena Corp Through The Eyes Of 5 Analysts - Benzinga
Prothena Corp (PRTA) Analyst Update: Price Target Significantly Lowered | PRTA Stock News - GuruFocus
Why Is Prothena Stock Trading Lower On Tuesday? - Benzinga
Jefferies Downgrades Prothena to Hold From Buy, Adjusts Price Target to $6 From $32 - marketscreener.com
Prothena Corp (PRTA) Price Target Lowered by HC Wainwright & Co. | PRTA Stock News - GuruFocus
Prothena stock price target cut to $14 at H.C. Wainwright By Investing.com - Investing.com UK
Chardan Adjusts PT on Prothena to $18 From $40 After Drug Removal From Model, Keeps Buy Rating - marketscreener.com
Prothena (PRTA) Price Target Slashed Following Clinical Trial Ou - GuruFocus
Prothena (PRTA) Faces Price Target Cut Following Trial Results | PRTA Stock News - GuruFocus
Prothena (PRTA) Target Price Slashed Following Study Setback | P - GuruFocus
Prothena (PRTA) Target Price Slashed Following Study Setback | PRTA Stock News - GuruFocus
Prothena (PRTA) Faces Setback with AFFIRM-AL Trial Results | PRTA Stock News - GuruFocus
Prothena Corporation Plc (PRTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Prothena Corporation Plc 주식 (PRTA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 10% Owner |
May 06 '25 |
Sale |
7.64 |
1,984,053 |
15,164,712 |
5,304,596 |
| EcoR1 Capital, LLC | 10% Owner |
May 05 '25 |
Sale |
8.11 |
977,693 |
7,930,166 |
7,288,649 |
| SCULLY WILLIAM P | 10% Owner |
Jan 14 '25 |
Buy |
12.79 |
100,000 |
1,279,040 |
735,993 |
| SCULLY WILLIAM P | 10% Owner |
Dec 18 '24 |
Buy |
13.93 |
73,436 |
1,022,670 |
1,297,693 |
| SCULLY WILLIAM P | 10% Owner |
Dec 31 '24 |
Buy |
13.01 |
32,000 |
416,393 |
650,193 |
| SCULLY WILLIAM P | 10% Owner |
Dec 20 '24 |
Buy |
15.91 |
2,000 |
31,813 |
618,693 |
1.76%
0.89%
자본화:
|
볼륨(24시간):